ALK-R3HDM1 and EML4-ALK fusion as a mechanism of acquired resistance to gefitinib: A case report and literature review

We report a case with a novel ALK-R3HDM1 and EML4-ALK dual fusion that might be a delicate mechanism for the acquired resistance of epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor (TKI). A patient with EGFR L858R lung adenocarcinoma developed disease progression after 72.7 months o...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Zhu, Wang, Tao, He, Junjun, Wang, Yuehong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9660230/
https://www.ncbi.nlm.nih.gov/pubmed/36387181
http://dx.doi.org/10.3389/fonc.2022.1010084

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9660230/
https://www.ncbi.nlm.nih.gov/pubmed/36387181
http://dx.doi.org/10.3389/fonc.2022.1010084

Ejemplares similares